Drug Combination Details
| General Information of the Combination (ID: C04317) | |||||
|---|---|---|---|---|---|
| Name | Triptolide NP Info | + | Vasostatin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Lung cancer
[ICD-11: 2C25]
|
Investigative | [1] | ||
|
Colon cancer
[ICD-11: 2B90]
|
Investigative | [1] | |||
|
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [1] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAD | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | BAK | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BCL-xL | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BIRC2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP8 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CFLAR | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MCL1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | |||
| HEK293 | CVCL_0045 | Healthy | Homo sapiens | |||
| QSG-7701 | CVCL_6944 | Human hepatocarcinoma | Homo sapiens | |||
| HUVEC | CVCL_2959 | Healthy | Homo sapiens | |||
| In-vivo Model | HCT116 cells in a solution containing 25 ml of culture medium and 25 ml of mouse sarcoma extracellular matrix (Matrigel) were injected subcutaneously into the dorsal flanks of mice. | |||||
| Experimental
Result(s) |
Herbal compound triptolide synergistically enhanced antitumor activity of vasostatin120-180. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Herbal compound triptolide synergistically enhanced antitumor activity of vasostatin120-180. Anticancer Drugs. 2013 Oct;24(9):945-57. | |||
